|Expense Ratio (net)||0.73%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||High|
|Beta (3Y Monthly)||1.60|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Dec 16, 1985|
A burgeoning economy and steady influx of funds make conditions ripe for diversification and further strengthening of the capital base.
The following is our latest Fund Analyst Report for Fidelity Select Health Care FSPHX . Morningstar Premium Members have access to full analyst reports such as this for more than 1,000 of the largest and best mutual funds. Fidelity Select Health Care's experienced, knowledgeable manager, deep resources, distinctive process, and relatively low costs earn the fund a Morningstar Analyst Rating of Silver.
Broadly encouraging economic conditions, favorable tax policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.
The fundamental performance goal for most investors is to outperform the S&P 500 Index, and a smart way to do this is with the best growth funds. As the common investment disclaimer reminds us, past performance is no guarantee of future results. But there’s also truth in the famous Mark Twain quote: “History doesn’t repeat itself but it often rhymes.”
Broadly encouraging economic conditions, favorable policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money.